CAR-T Cell Therapy for Non-Hodgkin’s Lymphoma

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma

 

Market Size of CAR T Cell Therapy for Non-Hodgkin's Lymphoma in the 6MM is anticipated to be USD 2796.2 Million in 2030.

Diffuse large B-cell Lymphoma (DLBCL) is the most common type of NHL, accounting for about 22% of newly diagnosed cases of B-cell NHL in the united states.

Advancements in technology, Increased collaborations & acquisitions and Competition among biotech & pharma giants are some of the factors expected to drive the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market in the coming years.

The key players in the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market include Novartis, Kite Pharma, Gilead Sciences, Celgene Corporation and others.

 

For more details visit:   

https://www.delveinsight.com/report-store/car-t-cell-therapy-for-non-hodgkins-lymphoma-market#utm_source=Infographic%20promotion&utm_medium=Infographic%20promotion&utm_campaign=Infographic%20promotion

#CARTCellTherapy #CellTherapy #CART #Lymphoma #NonHodgkinLymphoma